β2-adrenoreceptor medications and risk of Parkinson disease

Annals of Neurology

Volumn 84, Issue 5, 2018, Pages 683-693

  Searles Nielsen, Susan ^a   Gross, Anat ^a   Camacho Soto, Alejandra ^a   Willis, Allison W ^b   Racette, Brad A ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; CORTICOSTEROID; METOPROLOL; PRIMIDONE; PROPRANOLOL; SALBUTAMOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

AGED; ARTICLE; ASTHMA; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEMOGRAPHY; DRUG INDICATION; DYSKINESIA; EPILEPSY; FEMALE; HEALTH CARE UTILIZATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICARE; OXYGEN THERAPY; PARKINSON DISEASE; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; SMOKING; TREMOR; UNITED STATES;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; PARKINSON DISEASE;

EID: 85055879668     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.25341     Document Type: Article

References (25)

1. Mittal S, Bjornevik K, Im DS, et al. beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson's disease. Science 2017;357:891–898.
2. Searles Nielsen S, Warden MN, Camacho-Soto A, et al. A predictive model to identify Parkinson disease from administrative claims data. Neurology 2017;89:1448–1456.
3. Ripley TL, Saseen JJ. Beta-blockers: a review of their pharmacological and physiological diversity in hypertension. Ann Pharmacother 2014;48:723–733.
4. Poirier L, Tobe SW. Contemporary use of beta-blockers: clinical relevance of subclassification. Can J Cardiol 2014;30:S9–S15.
5. Deuschl G, Raethjen J, Hellriegel H, et al. Treatment of patients with essential tremor. Lancet Neurol 2011;10:148–161.
6. International nonproprietary names (INN) for pharmaceutical substances: lists 1-105 of proposed INN and lists 1-66 of recommended INN: cumulative list no. 14. Geneva, Switzerland: World Health Organization, 2011.
7. Sinnott SJ, Polinski JM, Byrne S, et al. Measuring drug exposure: concordance between defined daily dose and days' supply depended on drug class. J Clin Epidemiol 2016;69:107–113.
8. WHOCC ATC/DDD Index. Geneva, Switzerland: World Health Organization, 2018.
9. Gross A, Racette BA, Camacho-Soto A, et al. Use of medical care biases associations between Parkinson disease and other medical conditions. Neurology 2018;90:e2155–e2165.
10. Desai RJ, Solomon DH, Shadick N, et al. Identification of smoking using Medicare data—a validation study of claims-based algorithms. Pharmacoepidemiol Drug Saf 2016;25:472–475.
11. Centers for Disease Control and Prevention. BRFSS 2009 survey data and documentation. December 4, 2014. Available at: http://www.cdc.gov/brfss/annual_data/annual_2009.htm. Accessed May 17, 2016.
12. Ritz B, Ascherio A, Checkoway H, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 2007;64:990–997.
13. Hernan MA, Zhang SM, Rueda-deCastro AM, et al. Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. Ann Neurol 2001;50:780–786.
14. Hernan MA, Takkouche B, Caamano-Isorna F, et al. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52:276–284.
15. McLeish AC, Cougle JR, Zvolensky MJ. Asthma and cigarette smoking in a representative sample of adults. J Health Psychol 2011;16:643–652.
16. Selya AS, Oancea SC, Thapa S. Time to first cigarette, a proxy of nicotine dependence, increases the risk of pulmonary impairment, independently of current and lifetime smoking behavior. Nicotine Tob Res 2016;18:1431–1439.
17. Home Oxygen Therapy. Baltimore, MD: Centers for Medicare and Medicaid Services, 2017.
18. Stata MC, version 14.2. College Station, TX: StataCorp.
19. Goldstein BA, Bhavsar NA, Phelan M, et al. Controlling for informed presence bias due to the number of health encounters in an electronic health record. Am J Epidemiol 2016;184:847–855.
20. Psaty BM, Koepsell TD, Lin D, et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 1999;47:749–754.
21. Camacho-Soto A, Warden MN, Searles Nielsen S, et al. Traumatic brain injury in the prodromal period of Parkinson's disease: a large epidemiological study using medicare data. Ann Neurol 2017;82:744–754.
22. Nystrom H, Nordstrom A, Nordstrom P. Risk of injurious fall and hip fracture up to 26 y before the diagnosis of Parkinson disease: nested case-control studies in a nationwide cohort. PLoS Med 2016;13:e1001954.
23. Rugbjerg K, Ritz B, Korbo L, et al. Risk of Parkinson's disease after hospital contact for head injury: population based case-control study. BMJ 2008;337:a2494.
24. Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology 2011;77:1752–1755.
25. Koller WC, Biary N. Metoprolol compared with propranolol in the treatment of essential tremor. Arch Neurol 1984;41:171–172.